1Q FY2027 Cardinal Health, Inc. Earnings Conference - CARDINAL HEALTH INC

Explicit Guidance:

• FY2027 Non-GAAP EPS: Raised to $12.80–$13.00 (prior: $12.40–$12.60), representing 17–19% growth vs. FY26 ex-tariff refund adjusted EPS ($10.95) or 14–15% vs. reported FY26 EPS ($11.26).
• Pharma Segment (FY2027): Revenue growth guidance unchanged at 3–5%; segment profit growth raised to 10–12% (prior: 8–11%).
• Global Medical Products & Distribution (GMPD) Segment (FY2027): Revenue growth expected 2–4%; profit guidance unchanged at $200–$220 million, though current trajectory leans toward the low end due to petroleum costs.
• Other Segment (FY2027): Revenue growth raised to 12–14% (prior: 11–13%); profit growth raised to 17–20% (prior: 15–18%).
• Below-the-Line Items (FY2027): Interest and other expenses expected $240–$290 million; effective tax rate 18.5–19.5% (prior: 19–20%); capital expenditure ~$700 million (unchanged); diluted weighted average shares outstanding 231–232 million; adjusted free cash flow $3.5–$4.0 billion.
• Quarterly Cadence Expectation: FY27 earnings growth expected to moderate in Q2–Q3 before strengthening in Q4 to a level modestly below Q1 levels, driven by the timing of the Solaris acquisition lap and customer renewal impacts.

Business-Segment Outlook:

• Pharma: Specialty business growth (18% in Q1) driven by urology and oncology; generic volume growth outpacing long-term targets; Solaris acquisition integration on track with full-year impact lapping in Q2; long-term revenue stability supported by CVS renewal through June 2032 and other recent renewals covering ~2/3 of enterprise revenue.
• GMPD: Focus on "improvement plan" execution; organic U.S. brand growth expected in low-to-mid single digits; operational improvements expected to drive results weighted toward the back half of the fiscal year; AI-enabled automation deployed to 130 radio pharmacies by end of FY27.
• Other (Growth Businesses): At-home solutions expected to accelerate in H2 FY27 following Strive integration and new Sacramento DC construction; Nuclear/Precision Health leveraging AI route optimization (live in 20 sites, all 130 by FY27); OptiFrate expanding pharmacy tracking solutions.
• Synexis Patient Hub: On track to double therapies supported by FY28.
• 3PL Capacity: New St. Louis facility expected to start operations by end of Calendar Year 2027.

Market and Competitive Outlook:

• Demand Trends: Strong underlying secular trends in home-based care, complex medical innovation, and aging Asian population; continued high demand for GLP-1 medications (contributing ~500 bps to Q1 growth, offset by IRA WAC reductions).
• Competitive Position: Strategic "flywheel" effect between distribution, MSOs, and specialty platforms (e.g., urology ecosystem leveraging Solaris, Red Oak, and nuclear capabilities); focus on consolidating fragmented markets (MSOs, At-home, Nuclear).
• Pricing and Supply: IRA WAC reductions remain a headwind (~400 bps YoY); ongoing Iran conflict driving high petroleum costs impacting GMPD margins; Red Oak sourcing partnership expected to continue providing value beyond the 2029 contract term.
• Regulatory Impact (340B/OPPS): Anticipation that reimbursement changes may shift volume to Cardinal Health as providers navigate affordability; belief that federal intent is not to harm community providers where MSOs operate.

Macro / Industry Outlook:

• Economy/Politics: Election results and policy changes expected to be manageable; continued constructive engagement with policymakers across the political spectrum; no immediate expectation of disruptive policy shifts.
• FX and Tariffs: FX and distribution headwinds noted in GMPD; tariff tailwinds currently offsetting commodity/transportation costs; FY27 guidance assumes continued tariff impacts similar to FY26.
• Capital Allocation: Strong cash generation ($5.3B ending cash, $1.6B adjusted pre-tax cash flow in Q1) supporting disciplined capital deployment, potential M&A, and shareholder returns (dividends and buybacks).

Strategic Initiatives:

• M&A/Integration: Focus on integrating acquired assets (Solaris, Strive) and realizing synergies; active due diligence on fragmented MSO, at-home, and Biopharma Solutions opportunities; no "fourth leg" of the stool sought, focus remains on core three segments.
• Technology/AI: Deployment of 100+ autonomous robots in Dixon, CA; AI route optimization reaching full radio pharmacy network by FY27; AI infrastructure investments for productivity.
• Infrastructure: New Sacramento Distribution Center (At-home); new St. Louis 3PL facility (CY 2027); migration of Strive Medical employees/volume to nationwide network.
• Customer Relationships: Renewals covering nearly two-thirds of enterprise revenue; long-term stability enabling continued investment in growth.

Risks and Headwinds to Outlook:

• Commodity/Costs: Sustained high petroleum costs driven by the Iran conflict pushing GMPD profit to the low end of guidance.
• Regulatory: Potential impact from 340B/OPPS rule changes on provider volumes; IRA WAC reductions acting as a recurring revenue headwind.
• Geopolitical: Ongoing global volatility impacting supply chains and transportation costs.
• Execution Risks: Integration challenges associated with Solaris and other acquisitions; timing of customer renewals affecting quarterly sequencing.
• Market Dynamics: GLP-1 revenue growth could face headwinds or shifts; potential changes in generic market dynamics.

Management Tone on the Future:

• Confidence: High confidence in raising guidance based on "broad-based operating momentum" and "strong Q1 delivery"; management describes the start to FY27 as "excellent" and "strong."
• Strategic Clarity: Emphasis on "strengthening the core, scaling specialty, improving GMPD, and disciplined capital allocation."
• Hedges/Caveats: Management notes that while confidence is high, specific quarterly results will be impacted by the "timing of the year-over-year impact of customer renewals and lapping the Solaris acquisition," leading to expected moderation in Q2/Q3.
• M&A Stance: Cautiously optimistic; willing to execute on "creative, targeted M&A" but prioritizing integration of current assets and organic growth over opportunistic acquisitions that stray from the core strategy.

Miscellaneous:

• Dividend/Buyback: Executed $500M accelerated share repurchase in Q1; continuing return of ~$125M to shareholders via dividends; annual commitment of $1B buyback remaining (50% used).
• Q&A Highlights: Analyst questions focused on Q1 cadence drivers (specialty strength, generic volume), urology ecosystem synergies, and 340B regulatory impacts; management reiterated that urology represents a fragmented consolidation opportunity and that 340B impacts are likely second-order for the company.